[8-K] Dermata Therapeutics, Inc. Reports Material Event

Rhea-AI Filing Summary

Dermata Therapeutics filed an 8-K announcing it has filed a prospectus supplement to increase the maximum aggregate offering amount of common stock issuable under its At The Market Offering Agreement with H.C. Wainwright & Co., LLC by $1,792,315.

The company previously sold $1,662,142 of common stock under this agreement pursuant to a prior prospectus supplement. The filing also includes a legal opinion covering the additional $1,792,315 of shares tied to the Current Prospectus Supplement.

false 0001853816 0001853816 2025-11-07 2025-11-07 0001853816 DRMA:CommonStockParValue0.0001PerShareMember 2025-11-07 2025-11-07 0001853816 DRMA:WarrantsExercisableForOneShareOfCommonStockMember 2025-11-07 2025-11-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 7, 2025

DERMATA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-40739		86-3218736
(State or other jurisdiction		(Commission		(IRS Employer
of incorporation)		File Number)		Identification No.)

3525 Del Mar Heights Rd., #322 San Diego, CA		92130
(Address of principal executive offices)		(Zip Code)

(858) 800-2543

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of exchange on which registered
Common Stock, par value $0.0001 per share		DRMA		The Nasdaq Capital Market
Warrants, exercisable for one share of Common Stock		DRMAW		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 8.01 Other Events.

On November 7, 2025, Dermata Therapeutics, Inc. (the “Company”) filed a prospectus supplement (the “Current Prospectus Supplement”) to increase the maximum aggregate offering amount of the shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), issuable under the At The Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC, dated June 7, 2024, by an additional aggregate amount of $1,792,315. The Company previously sold $1,662,142 of shares of Common Stock pursuant to the Sales Agreement under a prior prospectus supplement. A copy of the legal opinion as to the legality of the $1,792,315 of shares of Common Stock issuable under the Sales Agreement and covered by the Current Prospectus Supplement is filed as Exhibit 5.1 attached hereto.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
5.1		Opinion of Lowenstein Sandler LLP
23.1		Consent of Lowenstein Sandler LLP (included in Exhibit 5.1)
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

-2-

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	DERMATA THERAPEUTICS, INC.
Dated: November 7, 2025	By:	/s/ Gerald T. Proehl
	Name:	Gerald T. Proehl
	Title:	President, Chairman and Chief Executive Officer

-3-

FAQ

What did DRMA disclose in its 8-K?

Dermata filed a prospectus supplement increasing the maximum aggregate offering amount of common stock under its ATM agreement by $1,792,315.

How much has DRMA already sold under the ATM?

The company previously sold $1,662,142 of common stock under the Sales Agreement pursuant to a prior prospectus supplement.

Who is the sales agent for DRMA’s ATM program?

H.C. Wainwright & Co., LLC is the sales agent under the At The Market Offering Agreement.

What legal exhibit is included with the filing?

An opinion of Lowenstein Sandler LLP covering the additional $1,792,315 of shares (Exhibit 5.1) and a related consent (Exhibit 23.1).

What securities are listed for Dermata (DRMA)?

Common Stock (ticker DRMA) and Warrants exercisable for one share of Common Stock (ticker DRMAW) on The Nasdaq Capital Market.